Semma Therapeutics, Backed by the T1D Fund, Acquired by Major Biopharma Company
In an exciting step forward in type 1 diabetes (T1D) research and development and for people with T1D, on September…
Breakthrough T1D Innovative Clinical Trial Design Workshop
BMC Medicine 16: 29 (2018)
Educators Align at the American Association of Diabetes Educators (AADE) Conference
Each year, diabetes educators from all over the world—including Nicole Johnson, DrPH, MPH, National Director, Breakthrough T1D Mission—gather for the…
The Type 1 Diabetes Digital Recipe Box
When you’re cooking to meet the needs of someone with type 1 diabetes (T1D), whether that be yourself, a family…
October 2019 Breakthrough T1D Young Adult Conference Speakers Announced
Breakthrough T1D’s Young Adult Conference is quickly approaching and we’re excited to announce our lineup of speakers! The event will…
Breakthrough T1D Hosts 3D Bioprinting Workshop for Type 1 Diabetes
Breakthrough T1D is committed to developing cell replacement therapies that will one day offer cures for type 1 diabetes (T1D).…
Gather your T1D back to school resources
Summer’s winding down and it is time to go back to school. With type 1 diabetes (T1D), back to school…
Triple Therapy in T1D: Breakthrough T1D Researchers Launch a Clinical Trial
Since its discovery nearly 100 years ago, insulin has been the only effective treatment for type 1 diabetes (T1D). Improvements…
Summer Internship Experience at Breakthrough T1D
By Jordan Garrick Ever since I was first diagnosed with type 1 diabetes (T1D), Breakthrough T1D has supported me through…
FDA Breakthrough Therapy Designation for Teplizumab—Based on the First Study to Delay the Onset of T1D for 2+ Years
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to teplizumab, an anti-CD3 monoclonal antibody, for the prevention…
